Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 6 August 2021, including: AstraZeneca PLC looks to return to normality; Bayer AG’s hopes for Kerendia; Novartis AG’s plans for a new version of Zolgensma; Arcturus Therapeutics Ltd. benefits from mRNA interest; and AbbVie Inc. changes tack in Alzheimer’s.
These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Bayer Backs Kerendia To Be A Blockbuster" - Scrip, 5 Aug, 2021.)
(Also see "Novartis Can Again Pursue Bigger Zolgensma Market After FDA Lifts OAV-101 Hold" - Scrip, 3 Aug, 2021.)
(Also see "Arcturus Leaps On COVID-19 Trials And Investor Interest In mRNA" - Scrip, 4 Aug, 2021.)
(Also see "AbbVie To Switch Track In Alzheimer’s From Tau To Beta-Amyloid" - Scrip, 30 Jul, 2021.)